Of note, eculizumab, ravulizumab, and inebilizumab have also been also approved for the treatment of generalized myasthenia gravis (gMG), which can co-occur with NMOSD,55and, in such cases, they may offer dual therapeutic benefits.56Moreover, IL-6 receptor-blocking mAbs (that is, satralizumab and tocilizumab) may be advantageous in patients with NMOSD and coexisting autoimmune diseases—such as rheumatoid arthritis, giant cell arteritis, or systemic sclerosis—in which IL-6 signaling plays a pivotal role in pathogenesis.15 This evidence concerns the gene IL6 and temporal arteritis.